Tang and colleagues reported that USP35 can directly stabilize FPN via its deubiquitinase activity (Figure 1); conversely, USP35 knockdown improves the sensitivity of lung cancer to paclitaxel (PTX) and cisplatin 19. Here, USP35 is linked to lung carcinoma.